Transforming Spine Surgery Through Personalized Solutions
Our mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The Carlsmed aprevo® personalized surgery platform is designed to improve the standard of care for spine surgery one patient at a time.
Our Core Values
We are committed to three guiding principles:
PATIENT-OBSESSED.
DO WHAT IS RIGHT.
ACHIEVE TOGETHER.
Executive Leadership Team
Mike Cordonnier
Chief Executive Officer
Mike Cordonnier
Chief Executive Officer
Mike Cordonnier is the Co-Founder, President and Chief Executive Officer at Carlsmed, and serves as the Chair of the Board of Directors.
With more than two decades of leadership experience introducing groundbreaking medical technologies, Mike has guided teams across both private and public organizations, including NuVasive, Ellipse Technologies, Zimmer Biomet, Orchid Orthopedics, and X-Spine Systems.
He holds a Bachelor of Science degree in Mechanical Engineering from the University of Dayton.
Leo Greenstein
Chief Financial Officer
Leo Greenstein
Chief Financial Officer
Leo is the Chief Financial Officer at Carlsmed.
Leo has over two decades of experience in business and finance. He has garnered expertise in the surgical device, pharmaceutical, and oncology diagnostics sectors. His leadership journey includes significant roles at prominent companies such as Spectrum Pharmaceuticals, Endologix, and most recently, Tarsus Pharmaceuticals.
Leo holds a Juris Doctor Degree from Temple University’s Beasley School of Law and Bachelor of Science Degree in Accounting from Arcadia University. He is a Certified Public Accountant and member of the California State Bar.
Jennifer Kamocsay
Chief Legal Officer
Jennifer Kamocsay
Chief Legal Officer
Jennifer is the Chief Legal Officer at Carlsmed and serves as Secretary of the Carlsmed Board of Directors.
She brings extensive legal expertise to Carlsmed, with a proven record of advising public life sciences and technology companies on complex corporate and regulatory matters. Prior to joining Carlsmed, she served as the Chief Legal Officer of Akoya Biosciences and held senior legal roles at Rubius Therapeutics and Progress Software Corporation.
Jennifer began her legal career at Skadden, Arps, Slate, Meagher & Flom LLP, representing biotechnology, pharmaceutical, and technology clients in the areas of mergers and acquisitions, securities law and corporate governance. She holds a J.D. from Northeastern University School of Law and a B.A. in History from UCLA.
Scott Durall
Chief Commercial Officer
Scott Durall
Chief Commercial Officer
Scott is the Chief Commercial Officer at Carlsmed.
With more than 30 years of experience in the medical device industry, Scott has held leadership roles across sales, marketing, and corporate strategy. His career includes successful tenures at U.S. Surgical Corporation, Boston Scientific Corporation, and NuVasive.
Scott holds a Bachelor of Business Administration in Marketing from the University of Kentucky.
Sharon Schulzki
Chief Clinical & Market Access Officer
Sharon Schulzki
Chief Clinical & Market Access Officer
Sharon is the Chief Clinical & Market Access Officer at Carlsmed.
Sharon’s extensive professional journey includes senior leadership roles in marketing and surgical affairs at prominent companies such as J&J and Stryker. She has also played crucial C-suite roles at successful startup ventures, namely Micropore Biosurgery, N-Spine, and Tissue Regeneration Systems, all of which achieved successful exits.
Sharon holds a Bachelor of Science degree in Medical Technology from Loyola University Maryland.
Shariq Hussain
Chief Technology Officer
Shariq Hussain
Chief Technology Officer
Shariq is the Chief Technology Officer at Carlsmed.
He has a strong track record of entrepreneurship and execution in technology and executive leadership roles at MedTech companies Intelliguard Solutions and Safety Syringes.
Shariq holds an MBA in Technology Management from National University, a B.S. in Computer Science and Engineering from UC San Diego, and another B.S. in Information Technology from National University.
Niall Casey
Chief Intellectual Property Officer
Niall Casey
Chief Intellectual Property Officer
Niall Casey is the Co-Founder and Chief Intellectual Property Officer at Carlsmed and serves on the Board of Directors.
A seasoned professional in the spine industry, Niall brings deep expertise from technology leadership roles at Alphatec Spine, Ellipse Technologies, NuVasive, and Johnson & Johnson DePuy Synthes Spine.
He holds a J.D. from Suffolk University, and M.S. and B.S. degrees in Biomedical Engineering from Case Western Reserve University.
Jeff Bertolini
Senior Vice President of Operational Excellence
Jeff Bertolini
Senior Vice President of Operational Excellence
Jeff is the Senior Vice President of Operational Excellence at Carlsmed.
With more than 30 years of experience in the medical device industry, Jeff has held leadership roles across Operations, Information Technology, Sales Operations, and corporate strategy. Prior to joining Carlsmed, he served in key positions at U.S. Surgical Corporation, SpineWave, and NuVasive.
Jeff completed the Chief Technology Officer (CTO) Program at the Wharton School of the University of Pennsylvania. He holds an MBA from Rensselaer Polytechnic Institute and a Bachelor of Science in Operations and Materials Management from Arizona State University.
Jodi Allen
Senior Vice President, People and Culture
Jodi Allen
Senior Vice President of People and Culture
Jodi is the Senior Vice President of People and Culture at Carlsmed.
She brings over a decade of experience leading strategic planning and business intelligence across both public and private organizations, most recently at NuVasive.
Jodi holds an MBA from California State University and a Bachelor of Arts in Political Science from the University of Illinois.
Julie Lamothe
Vice President of Regulatory Affairs & Quality Assurance
Julie Lamothe
Vice President of Regulatory Affairs & Quality Assurance
Julie Lamothe is the Vice President of Regulatory Affairs & Quality Assurance at Carlsmed.
She brings over 15 years of experience in the medical industry, including more than a decade focused on spine technologies. Julie’s deep expertise in microbiology, industrial sterilization, and biocompatibility helps ensure the safety and compliance of Carlsmed’s products across global markets.
Julie holds a Ph.D. in Microbiology and Immunology and an MBA from the Rady School of Management at UC San Diego — a unique blend of scientific depth and strategic leadership that drives regulatory excellence at Carlsmed.
Mike Cordonnier
Chief Executive Officer
Mike is the co-founder and serves as Chief Executive Officer and President of Carlsmed, he also serves as Chairman of the Board of Directors.
Mike has over two decades of experience successfully leading teams in introducing groundbreaking medical technologies. He possesses extensive operational expertise in both private and public companies, having contributed to the success of organizations such as NuVasive, Ellipse Technologies, Zimmer Biomet, Orchid Orthopedics, and X-Spine Systems.
Mike holds a Bachelor of Science degree in Mechanical Engineering from the University of Dayton.
Board of Directors
Mike Cordonnier is the Co-Founder, President and Chief Executive Officer at Carlsmed, and serves as the Chair of the Board of Directors.
With more than two decades of leadership experience introducing groundbreaking medical technologies, Mike has guided teams across both private and public organizations, including NuVasive, Ellipse Technologies, Zimmer Biomet, Orchid Orthopedics, and X-Spine Systems.
He holds a Bachelor of Science degree in Mechanical Engineering from the University of Dayton.
He is currently a board member at Intrinsic Therapeutics, Miach Orthopaedics, Razor Medical, FzioMed, Shoulder Innovations, and Moximed. He previously served on the boards of Rotation Medical, Ceterix, and Pivot Medical.
Kevin is the former CEO of St. Francis Medical Technologies and Moximed. He formerly served as Worldwide President of Johnson & Johnson’s DePuy Orthopedics.
He earned a Bachelor of Science in Accounting from West Virginia University.
Kevin O’Boyle serves as Chair of the Audit Committee and is a member of the Compensation Committee on the Carlsmed Board of Directors.
He currently serves on the board of Nevro (NVRO) and has previously served as a director of seven publicly traded companies, including Wright Medical Group (WMGI), GenMark Diagnostics (GNMK), and Zeltiq (ZLTQ).
Kevin is a former Senior Vice President and CFO of Advanced BioHealing and CFO of NuVasive, as well as CFO and COO of ChromaVision Medical Systems, and CFO and SVP of Operations at Albert Fisher Group PLC.
He holds a Bachelor of Science in Accounting from the Rochester Institute of Technology and completed the Executive Program at UCLA Anderson School of Management.
Dr. Jonathan Root serves as Chair of the Nominating and Corporate Governance Committee on the Carlsmed Board of Directors.
He is a General Partner at U.S. Venture Partners and currently serves on the boards of Edgewise Therapeutics, Inari Medical, Silverback Therapeutics, Cleave Therapeutics, HealthJoy, Okami Medical, Omada Health, Nuvaira, Ribon Therapeutics, Route 92 Medical, and Sparrow Pharmaceuticals.
Previously, he served on the boards of eFFECTOR Therapeutics, Lutonix, Microvention, OncoMed Pharmaceuticals, Sequent Medical, and Proteolix.
Prior to joining U.S. Venture Partners, Dr. Root was an Assistant Professor of Neurology and Director of the Neurology–Neurosurgery Special Care Unit at Cornell Medical Center.
He earned his M.D. from the University of Florida College of Medicine, an M.B.A. from Columbia University, and an A.B. in Economics from Dartmouth College.
Dr. Robert Mittendorf serves as a member of the Compensation Committee and the Nominating and Corporate Governance Committee on the Carlsmed Board of Directors.
He is a General Partner and Head of Healthcare at B Capital, where he leads venture and growth investments across the sector. His team has led investments in Hotspot Therapeutics, Lively, Aetion, Oncomyx, and Triumvira OR, where he also serves as Board Director or Observer.
Dr. Mittendorf previously held leadership or board roles with companies including Impel NeuroPharma, Silk Road Medical, TigerConnect, Avalyn Pharma, Neocis, Telcare, VisitPay, IntersectENT, iRhythm, Omada, Talkspace, and iCardiac.
Before his venture capital career, Dr. Mittendorf led Marketing and Business Development at Hansen Medical.
He earned an M.D. from Harvard University, an M.B.A. from Harvard Business School, an M.S. in Systems Engineering from MIT, and an M.A. in International Relations from King’s College London.
He is a Senior Advisor at U.S. Venture Partners, following two decades as a Managing General Partner.
Phil has served on numerous boards, including Aerogen, Aptus Endosystems, CardioThoracic Systems, CardioVascular Imaging Systems, CoCensys, Compugen, Dotomi, FemRx, HeartFlow, La Jolla Pharmaceuticals, Penederm, 3Dfx Interactive, RelayHealth, SentreHEART, Simpirica Spine, Synarc, St. Francis Medical Technologies, The Immune Response Corporation, Vical, Xoma, and Zoran.
Earlier in his career, he was President and CEO of Oximetrix and served on the Board of Trustees of Cornell University, where he chaired eCornell for nearly 20 years.
Phil earned an M.B.A. from Harvard Business School, an M.S. in Engineering Physics from George Washington University, and a B.M.E. from Cornell University.
Niall Casey is the Co-Founder and Chief Intellectual Property Officer at Carlsmed and serves on the Board of Directors.
A seasoned professional in the spine industry, Niall brings deep expertise from technology leadership roles at Alphatec Spine, Ellipse Technologies, NuVasive, and Johnson & Johnson DePuy Synthes Spine.
He holds a J.D. from Suffolk University, and M.S. and B.S. degrees in Biomedical Engineering from Case Western Reserve University.
Paving the Way for the Future of Spinal Fusion Surgery
First company to receive FDA Breakthrough Device Designation for Intervertebral Spine Fusion Technology
2020
July
aprevo® Lumbar receives FDA Breakthrough Device Designation
December
FDA 510(k) clearance granted for aprevo® Lumbar
2021
February
First aprevo® ALIF procedure performed in a patient
June
First aprevo® LLIF procedure performed in a patient
August
First aprevo® TLIF-O procedure performed in a patient
October
aprevo® Lumbar receives CMS NTAP reimbursement and TPT payment approval
2022
August
First aprevo® TLIF-C procedure performed in a patient
October
Enrollment begins for the COMPASS™ personalized spine surgery study
2023
January
First aprevo® ALIF-X procedure performed in a patient
September
Carlsmed receives second FDA Breakthrough Device Designation for cervical technology
2024
August
First aprevo® TLIF-CA procedure performed in a patient
November
Launch of Carlsmed’s cutting-edge digital production line
December
FDA 510(k) clearance granted for aprevo® Cervical
2025
June
First aprevo® Lumbar Angled Solutions procedure performed in a patient
July
First aprevo® ACDF procedure performed in a patient
July
First aprevo® ACDF-X procedure performed in a patient
July
Carlsmed completes Initial Public Offering and begins trading on Nasdaq
August
